Ozmosi | Cinepazide Drug Profile

Product Description

Cinepazide is an olefinic compound. It derives from a cinnamic acid.Cinepazide has been used in trials studying the treatment of Ischemic Stroke. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cinepazide)

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Korea

Approved Indications: None

Known Adverse Events: None

Company: Sihuan Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Ischemic Stroke

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20231896	CTR20231896	N/A	Completed	Ischemic Stroke	2023-07-26	2025-04-29	Patient Enrollment\|Treatments
ChiCTR1900023827	ChiCTR1900023827	N/A	Not yet recruiting	Ischemic Stroke	2019-06-30
ChiCTR-IIR-16008180	ChiCTR-IIR-16008180	N/A	Recruiting	Ischemic Stroke	2017-06-30
NCT04951232	D2016058	N/A	Completed	Ischemic Stroke	2017-01-06	2021-07-07	Primary Endpoints
ChiCTR-TRC-11001372	ChiCTR-TRC-11001372	N/A	Completed	Ischemic Stroke	2011-12-31
CTR20170346	CTR20170346	N/A	Recruiting	Ischemic Stroke	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
NCT01851759	xijing005	P2	Unknown status	Ischemic Stroke	2014-08-01	2019-03-19	Treatments
CTR20140186	CTR20140186	P2	Recruiting	Ischemic Stroke	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20160292	CTR20160292	P4	Completed	Ischemic Stroke	2019-02-01	2025-04-29	Patient Enrollment\|Treatments
CTR20160417	CTR20160417	P4	Completed	Ischemic Stroke	2018-05-31	2025-04-29	Patient Enrollment\|Treatments
CTR20170218	CTR20170218	P4	Recruiting	Ischemic Stroke	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20160762	CTR20160762	P4	Recruiting	Ischemic Stroke	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
01/06/2024	PubMed	Broad Spectrum Enantioselective Amide Bond Synthetase from Streptoalloteichus hindustanus.
09/13/2023	News Article	The Cinepazide Maleate market's types, applications, and regional analysis are all thoroughly covered in this report, with a projected CAGR of 10% for the 2023 - 2030 period.
09/13/2023	News Article	Paroxetine Mesylate market study report offers opportunities for social, economic, and international and this market is growing with a CAGR of 9% until 2030
06/01/2023	PubMed	Cinepazide maleate promotes recovery from spinal cord injury by inhibiting inflammation and prolonging neuronal survival.
08/01/2022	PubMed	[Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension].
05/31/2019	News Article	Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Cinepazide

Alternative Names: cinepazide Clinical Status: Inactive Latest Update: 2024-01-06 Latest Update Note: PubMed Publication